Lexology May 9, 2022
Latham & Watkins LLP

Drug Pricing Initiatives: In advance of the midterm elections in November, discussion continues in Congress and among stakeholders of drug pricing reform measures, including those that were originally part of H.R. 5376 (the Build Back Better Act, or BBBA). Sources: InsideHealthPolicy, STAT (link, link) 2023 Budget Hearings: On April 27, 2022, Xavier Becerra, Secretary of the Department of Health and Human Services (HHS), appeared at a congressional budget hearing, where he faced a broad discussion of HHS priorities and the agency’s responsiveness to information requests from Congress. Sources: BioWorld, Bloomberg Law, Politico Pro

Medicare Part D Rule Promises Beneficiary and Manufacturer Cost Savings: The Centers for Medicare and Medicaid Services (CMS) issued a final rule (with an accompanying fact sheet)...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Healthcare System, Insurance, Medicare, Pharma, Pharma / Biotech, Pricing / Spending
Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA
Cerevel Parkinson’s data adds lustre to AbbVie acquisition
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
Pharma Pulse 4/19/24: The Health and Healthcare of Gen-Z, Long-Acting Drugs May Revolutionize HIV Prevention/Treatment & more
Recursion, Canaan, Metsera and more—Chutes & Ladders

Share This Article